A new trading day began on Friday, with Capricor Therapeutics Inc (NASDAQ: CAPR) stock price down -10.45% from the previous day of trading, before settling in for the closing price of $14.36. CAPR’s price has ranged from $3.52 to $23.40 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 406.13%. Meanwhile, its annual earnings per share averaged 34.04%. With a float of $39.94 million, this company’s outstanding shares have now reached $45.58 million.
Let’s determine the extent of company efficiency that accounts for 102 employees. In terms of profitability, gross margin is 31.55%, operating margin of -191.13%, and the pretax margin is -181.71%.
Capricor Therapeutics Inc (CAPR) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Capricor Therapeutics Inc is 12.16%, while institutional ownership is 39.05%. The most recent insider transaction that took place on Sep 20 ’24, was worth 14,999,998. In this transaction 10% Owner of this company bought 2,798,507 shares at a rate of $5.36, taking the stock ownership to the 7,090,351 shares.
Capricor Therapeutics Inc (CAPR) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 34.04% per share during the next fiscal year.
Capricor Therapeutics Inc (NASDAQ: CAPR) Trading Performance Indicators
Here are Capricor Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 4.19. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 26.26.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.20, a number that is poised to hit -0.31 in the next quarter and is forecasted to reach 0.04 in one year’s time.
Technical Analysis of Capricor Therapeutics Inc (CAPR)
Looking closely at Capricor Therapeutics Inc (NASDAQ: CAPR), its last 5-days average volume was 1.93 million, which is a jump from its year-to-date volume of 1.17 million. As of the previous 9 days, the stock’s Stochastic %D was 52.34%. Additionally, its Average True Range was 1.33.
During the past 100 days, Capricor Therapeutics Inc’s (CAPR) raw stochastic average was set at 11.54%, which indicates a significant decrease from 28.35% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 113.65% in the past 14 days, which was higher than the 92.49% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $14.01, while its 200-day Moving Average is $11.45. However, in the short run, Capricor Therapeutics Inc’s stock first resistance to watch stands at $13.76. Second resistance stands at $14.67. The third major resistance level sits at $15.17. If the price goes on to break the first support level at $12.35, it is likely to go to the next support level at $11.85. Should the price break the second support level, the third support level stands at $10.94.
Capricor Therapeutics Inc (NASDAQ: CAPR) Key Stats
With a market capitalization of 584.74 million, the company has a total of 45,470K Shares Outstanding. Currently, annual sales are 25,180 K while annual income is -22,290 K. The company’s previous quarter sales were 2,260 K while its latest quarter income was -12,560 K.
